Evidence for the Immunosuppressive Potential of Calcineurin Inhibitor-Sparing Regimens in Liver Transplant Recipients with Impaired Renal Function
2011

Immunosuppressive Regimens in Liver Transplant Recipients with Renal Function Issues

Sample size: 60 publication Evidence: moderate

Author Information

Author(s): Kentaro Ide, Yuka Tanaka, Takashi Onoe, Masataka Banshodani, Hirofumi Tazawa, Yuka Igarashi, Nabin Bahadur Basnet, Marlen Doskali, Hirotaka Tashiro, Hideki Ohdan

Primary Institution: Hiroshima University

Hypothesis

Can calcineurin inhibitor-sparing regimens improve renal function in liver transplant recipients with renal insufficiency?

Conclusion

Calcineurin inhibitor-sparing regimens improve renal function in liver transplant patients with renal insufficiency without increasing rejection rates.

Supporting Evidence

  • 68% of patients had none to mild renal insufficiency before transplantation.
  • 32% of patients had moderate to severe renal insufficiency before transplantation.
  • One year after transplantation, the mean eGFR in the renal insufficiency group improved significantly.
  • 53% of patients in the renal insufficiency group were completely cured of renal insufficiency by one year after transplantation.

Takeaway

This study shows that patients who had kidney problems before liver transplants can have better kidney function after using a special medicine plan that doesn't rely on certain drugs that can harm the kidneys.

Methodology

The study involved 60 liver transplant patients, comparing those with renal insufficiency receiving a calcineurin inhibitor-sparing regimen to those without renal insufficiency receiving standard treatment, monitoring renal function and immune responses.

Potential Biases

The groups were not perfectly comparable, as renal impairment can affect immune responses.

Limitations

The study had a small sample size and was conducted at a single center, which may limit the generalizability of the findings.

Participant Demographics

34 males and 26 females, ages ranged from 20 to 69 years, with various liver disease etiologies.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1155/2011/483728

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication